Lonnie P. Swift

TL;DR: It is shown that doxorubicin-DNA adducts induce a more cytotoxic response in HL-60 cells than doxorbicin as a single agent, and that theseAdducts are more cytOToxic than topoisomerase II-mediated lesions.

TL;DR: It is shown that purified human SNM1A (hSNM 1A), which exhibits a 5'-3' exonuclease activity, can load from a single DNA nick and digest past an ICL on its substrate strand.

TL;DR: Analysis of protein kinases with respect to cell cycle progression indicates that ATR is required for G(2)/M checkpoint responses while ATM appears to function in G(1) mediated responses to anthracycline adducts, which may be potential drug targets to achieve synergistic cytotoxic responses to doxorubicin-DNA adduct forming therapies.

TL;DR: It is shown that when Adriamycin is used in conjunction with the formaldehyde-releasing prodrug AN-9 in IMR-32 tumor cells, this allows the formation of sufficiently high levels of adducts in genomic DNA to enable detection of their DNA sequence specificity for the first time.

TL;DR: HMTA has some potential for localized activation of Adriamycin in solid tumors because it is known to hydrolyze under cellular conditions and release six molecules of formaldehyde in a pH-dependent manner.